PARP1

Poly [ADP-ribose] polymerase 1

299,240 patent compounds predicted against PARP1, 153,826 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Azd2461 (SCHEMBL77012)	1.00	20/20
SCHEMBL76871	0.84	20/20
SCHEMBL77298	0.83	20/20
SCHEMBL78156	0.83	20/20
SCHEMBL78202	0.82	20/20
SCHEMBL79067	0.82	20/20
SCHEMBL78550	0.81	20/20
SCHEMBL77230	0.81	20/20
SCHEMBL77632	0.81	20/20
SCHEMBL78306	0.80	20/20
SCHEMBL77315	0.79	20/20
SCHEMBL76798	0.79	20/20
SCHEMBL78533	0.79	20/20
SCHEMBL78072	0.79	20/20
SCHEMBL79291	0.78	20/20
SCHEMBL78517	0.77	20/20
SCHEMBL77391	0.75	20/20
SCHEMBL77305	0.75	20/20
SCHEMBL77530	0.75	20/20
SCHEMBL78326	0.75	20/20

Germline variants in PARP1 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full PARP1 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to PARP1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients	PHASE3	COMPLETED
Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments	PHASE3	COMPLETED
A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib	PHASE2	COMPLETED
Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment	PHASE2	ACTIVE_NOT_RECRUITING
A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Phase II ABT-888 With Cyclophosphamide	PHASE2	COMPLETED
Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy	PHASE1/PHASE2	UNKNOWN
Olaparib In Metastatic Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations	PHASE1/PHASE2	COMPLETED
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies	PHASE1/PHASE2	RECRUITING
A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer	PHASE2	ACTIVE_NOT_RECRUITING
A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure	PHASE2	UNKNOWN
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer	PHASE1	UNKNOWN
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer	PHASE1	ACTIVE_NOT_RECRUITING
Pre-Operative Radiation and Veliparib for Breast Cancer	PHASE1	COMPLETED
Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer	PHASE1	ACTIVE_NOT_RECRUITING
Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors	PHASE1	COMPLETED
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers	PHASE1	COMPLETED
ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems	PHASE1	WITHDRAWN
Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts	PHASE1	ACTIVE_NOT_RECRUITING
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors	PHASE1	COMPLETED
Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer	PHASE1	COMPLETED
A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients	PHASE1	ACTIVE_NOT_RECRUITING
PET Imaging of PARP Activity in Cancer	EARLY_PHASE1	UNKNOWN
Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer	nan	NO_LONGER_AVAILABLE
Sirtuin1 in COVID19 Patients	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PARP1 binder may also engage these)

Protein	Name	Similarity
P31669	—	1.000	P31669 →
P27008	—	1.000	P27008 →
P26446	—	1.000	P26446 →
P18493	—	1.000	P18493 →
Q9R152	—	1.000	Q9R152 →
P11103	—	0.999	P11103 →
Q5RHR0	—	0.999	Q5RHR0 →
Q11208	—	0.995	Q11208 →
Q9ZSV1	—	0.991	Q9ZSV1 →
Q9ZP54	—	0.989	Q9ZP54 →
Q5Z8Q9	—	0.987	Q5Z8Q9 →
O50017	—	0.985	O50017 →
P35875	—	0.984	P35875 →
Q5ZJM3	—	0.984	Q5ZJM3 →
Q803R5	—	0.984	Q803R5 →
Q07205	—	0.984	Q07205 →
Q6DDS9	—	0.983	Q6DDS9 →
Q23670	—	0.983	Q23670 →
Q7SH49	—	0.982	Q7SH49 →
O13046	—	0.982	O13046 →
Q7SXS8	—	0.982	Q7SXS8 →
LIG3	DNA ligase 3	0.982	landscape →
Q9C8F1	—	0.982	Q9C8F1 →
P97386	—	0.982	P97386 →
P55010	—	0.982	P55010 →
Q7EYV7	—	0.982	Q7EYV7 →
Q9SWB4	—	0.981	Q9SWB4 →
LIG4	DNA ligase 4	0.981	landscape →
Q64511	—	0.981	Q64511 →
Q4R4I6	—	0.981	Q4R4I6 →